美股大盤綜合信息報導

永遠敬畏市場:試用K線技術分析探尋美股大盤走勢
Always trade what you see, instead of what you think!
個人資料
正文

為什麽今天捏住MNKD不放鬆?

(2014-06-16 20:30:51) 下一個

為什麽今天捏住MNKD不放鬆?

老博今天發帖,好心勸告MNKD股票持有者暫時放棄,因為三重頂阻力巨大。言之有理!

然而,我仔細看了下目前的形勢,決定暫時不動。原因如下:
1. K線圖日線顯示: MNKD上周五擺出旭日東升之上升態勢。今天MNKD低開高走展示其上升動能之潛力。
2. 今天MNKD拉出上影線小陽線試探空方阻力。 期待明後天的大陽線上竄 。。。。。。
3. 隻要本周大盤走高,本周MNKD多方就要上衝$11-$11.50 。。。。。。

MNKD過去半年日線10天均線走勢圖:


本帖隻是表明個人看盤和操作決定。不是投資交易參考。
本人無意與任何人爭論應當在MNKD何價位何時買進或賣出手中籌碼。但是,我買進賣出都會及時告知。
股市交易有風險,高位跟風要謹慎!
買賣自斷,盈虧與本帖無關!
 

[ 打印 ]
閱讀 ()評論 (3)
評論
FirstInfo 回複 悄悄話 Web Reference: http://seekingalpha.com/article/2270393-pricing-mannkind-corporation-the-sequel

MNKD Highest Price:
A Brief Review

As we saw last summer, the future held four possible paths for MannKind. The first, and shortest, had Afrezza failing to meet its objectives in clinical trials and MNKD stock dropping to penny stock status. The other three had the inhaled insulin product achieving success in the trials, leading to MannKind being acquired; securing a marketing partner; or deciding to commercialize on its own. As detailed in the two articles mentioned above, the takeover scenario suggested a 12-month buyout price of $27.50 a share; the partnership $28.00, and going it alone $27.42.
FirstInfo 回複 悄悄話 回複 'D&D' 的評論 :
不客氣!
D&D 回複 悄悄話 謝謝專業分析!
登錄後才可評論.